The safety of SPINRAZA® has been established in a broad range of patients treated for up to 5 years1

Safety assessments of SPINRAZA® are based on multiple Phase III, Phase II and open-label studies and include 346 patients, aged from newborns to young adults, who received SPINRAZA® for up to 5 years.1

The long-term safety of SPINRAZA® is being evaluated in ongoing open-label studies in patients with infantile-onset (Type I) and later-onset (Type II/III).1

Adverse reactions related to lumbar puncture reported in CHERISH with an incidence ≥5% higher in SPINRAZA®-treated patients than sham-control patients.1

Table
*Adverse events considered related to the lumbar puncture procedure.
These events can be considered manifestations of post-lumbar puncture syndrome.
Information banner

Bill
age 48*
Later-onset (Type III) SMA
treated with SPINRAZA®

*Age at time of photo shoot.

References:
1. SPINRAZA® Summary of Product Characteristics.